Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

WAYNE, Pa., April 1, 2024  -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

The UroLift™ 2 System is a market leader and proven minimally invasive treatment for BPH that provides an effective alternative to BPH medications and major surgery.^1,2 The UroLift™ 2 ATC represents a breakthrough in BPH treatment, with its adaptable design that enables physicians to customize treatments to each patient’s unique anatomy, and allows a personalized approach to help maximize effectiveness.

The UroLift™ 2 ATC System offers physicians enhanced confidence, improved control of obstructive tissue and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise.³ A streamlined delivery system, utilizing one handle per procedure and individual implant cartridges, also ensures increased physician comfort and improves efficiency during the procedure.³

“UroLift™ 2 ATC optimizes enlarged prostate treatment by providing urologists with unparalleled confidence and customization capabilities,” said Jake Newman, President, The Americas,  Teleflex. “The UroLift™ 2 System with ATC offers a comprehensive solution for BPH care, combining cutting-edge technology with proven clinical outcomes.¹ Our innovative platform streamlines procedures and eliminates the need to transition between platforms during a procedure. Enhanced features, including greater and more consistent implant compression and reduced waste, will help drive outcomes and efficiency in healthcare delivery.”

Brian Wilkins, Vice President of Research and Development for Teleflex Interventional Urology, added, “The UroLift™ 2 ATC is designed to deliver the same proven effectiveness of the UroLift™ System, with significant enhancements on a unified UroLift™ 2 platform. Based on physician feedback, it maintains the efficacy of the UroLift™ System, improves overall performance, and offers physicians the advantage of efficiently treating a broader range of patients.³ This expanded capability offered by UroLift™ 2 ATC opens new avenues for patient care.”

“The UroLift™ 2 ATC is a game-changer. Bringing the enhanced tissue control capabilities onto the innovative and proven UroLift™ 2 platform allows me to deliver unparalleled precision to treat a broad spectrum of patients and anatomies. It has transformed my approach to BPH care,” said Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana.

Dr. Mark Pe with Genesis Urology in San Diego, California added, “I find it immensely helpful to have UroLift™ 2 ATC stocked and readily available at every procedure in case additional tissue control is needed. It ensures I’m always equipped to treat a broad range of patients with unique prostate types and anatomies.”

To learn more about UroLift™ 2 ATC, visit UroLift.com.

About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,⁴ relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.^5-6 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*^7-8 A study conducted over 5 years showed a low retreatment rate of about 2-3% per year, or a total of 13.6% over the course of the study, demonstrating UroLift™ System durability.¹ Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.⁹ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. 475,000 men have been treated with the UroLift™ System in select markets worldwide.¹⁰ Learn more at www.UroLift.com. Rx only.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Contacts:

Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
Investors.teleflex.com
610-948-2836